您的位置: 首页 > 农业专利 > 详情页

LA COMBINAISON INHIBITEURS ABCG2-SACITUZUMAB GOVITECAN (IMMU-132) SURMONTE LA RESISTANCE A SN-38 DANS LES CANCERS EXPRIMANT TROP-2
专利权人:
IMMUNOMEDICS; INC.
发明人:
CHANG, CHIEN-HSING,GOLDENBERG, DAVID M.
申请号:
CA3011372
公开号:
CA3011372A1
申请日:
2017.02.10
申请国别(地区):
CA
年份:
2017
代理人:
摘要:
The present invention relates to therapeutic ADCs comprising a drug attached to an anti-cancer antibody or antigen-binding antibody fragment. Preferably the drug is SN-38. More preferably the antibody or fragment thereof binds to Trop-2 and the therapy is used to treat a Trop-2 positive cancer. Most preferably the antibody is hRS7. The ADC is administered to a subject with a cancer in combination with an ABCG2 inhibitor. The combination therapy is effective to treat cancers that are resistant to drug alone and/or to ADC alone.
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充